Research Keyword: Leukemia

Endogenous Endophthalmitis: An underestimated serious complication in patients with disseminated fusariosis

mycolabadmin

An 18-year-old leukemia patient developed a serious fungal eye infection from Fusarium during cancer treatment. The infection spread through the bloodstream to both eyes, causing serious inflammation and vision loss. Doctors treated it with multiple antifungal medications injected directly into the eyes along with systemic medication, which controlled the infection but unfortunately the patient’s vision was significantly affected. This case highlights how rare but serious eye infections can occur in cancer patients with weakened immune systems.

Read More »

Isavuconazonium Utilization in Pediatric Patients at a Free-Standing Children’s Hospital

mycolabadmin

Researchers at Children’s Hospital Los Angeles studied how well a newer antifungal medication called isavuconazonium works in children with cancer and blood disorders who are at high risk for serious fungal infections. The medication was recently approved for use in children ages 1 and older. The study found that the medication was generally safe and effective, though doctors need to monitor liver function and drug levels to ensure proper dosing and catch any side effects early.

Read More »

Active Hexose-Correlated Compound Shows Direct and Indirect Effects against Chronic Lymphocytic Leukemia

mycolabadmin

Researchers tested a mushroom-derived supplement called AHCC against chronic lymphocytic leukemia in laboratory and animal studies. AHCC killed leukemia cells directly and also reduced supportive cells in the tumor environment. When combined with antibody therapy, AHCC significantly improved outcomes in mouse models, suggesting it could be a promising addition to current leukemia treatments.

Read More »

Marine-derived Acremonium strain prioritization using untargeted metabolomics approach for the identification of cytotoxic cyclic depsipeptides

mycolabadmin

Researchers studied six fungal strains from Arctic driftwood to find cancer-fighting compounds. Using advanced chemical analysis methods, they identified one strain that was particularly good at killing cancer cells in the lab. From this strain, they isolated five related compounds called depsipeptides that showed strong activity against multiple types of cancer cells. This discovery highlights how fungi from extreme environments like the Arctic could be valuable sources for developing new cancer treatments.

Read More »

Marine-derived Acremonium strain prioritization using untargeted metabolomics approach for the identification of cytotoxic cyclic depsipeptides

mycolabadmin

Researchers studied fungi collected from Arctic driftwood to find new cancer-fighting compounds. Using advanced chemical analysis tools, they identified six different fungal strains and found that one strain, Acremonium synnematoferum, produced five unique compounds called depsipeptides. These compounds killed cancer cells in laboratory tests, showing promise as potential cancer treatments. This research highlights how extreme Arctic environments can harbor fungi with powerful medicinal properties.

Read More »

Cytotoxic activity of Ganoderma weberianum-sichuanese isolated from the Lower Volta River Basin of Ghana against human prostate carcinoma (PC-3), leukemic T cell (Jurkat), and plasmacytoid dendritic cell (pDC)-derived acute leukemia (PMDC05) cell lines

mycolabadmin

Researchers tested a fungus called Ganoderma weberianum-sichuanese from Ghana’s Lower Volta River to see if it could kill cancer cells. They found that extracts from this fungus could effectively suppress the growth of three types of human cancer cells—prostate cancer, T-cell leukemia, and a rare dendritic cell leukemia—without harming normal liver cells. The most promising components were found in certain fractions of the extract, suggesting this natural fungus could potentially be developed into new cancer treatments.

Read More »
Scroll to Top